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Abstract
Background: Radiotherapy (RT) is one of the major non-operative treatment modalities for treating lung cancer.
Tomotherapy is an advanced type of intensity-modulated radiotherapy (IMRT) in which radiation may be delivered
in a helical fashion. However, unexpected pneumonitis may occur in patients treated with tomotherapy, especially
in combination with chemotherapy, as a result of extensive low-dose radiation of large lung volumes. The aim of
our study was to investigate the risk of radiation-induced pneumonitis after helical-mode and static-mode tomotherapy
in patients with lung cancer and in an animal model.
Method: A total of 63 patients with primary lung cancer who were treated with static or helical tomotherapy with or
without concurrent chemoradiotherapy (CCRT) were analyzed. Additionally, rats with radiation-induced pulmonary
toxicity, which was induced by the application of helical or static tomography with or without CCRT, were evaluated.
Results: Helical-mode tomotherapy resulted in a significantly higher rate of late radiation pneumonitis in lung cancer
patients than static-mode tomotherapy when evaluated by the Radiation Therapy Oncology Group (RTOG) and National
Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) scoring system. In the animal model, helical
tomotherapy alone induced significantly higher expression of interleukin (IL)-1α, IL-1β, IL-6, and transforming growth
factor (TGF)-β in lung specimens, especially on the untreated side, compared to static tomotherapy alone. Additionally,
rats treated with helical tomotherapy and CCRT demonstrated significantly higher expression of inflammatory cytokines
compared to those treated with static tomotherapy and CCRT.
Conclusion: Rat models treated with tomotherapy with or without CCRT could present similar patterns of pulmonary
toxicity to those shown in lung cancer patients. The models can be used in further investigations of radiation induced
pulmonary toxicity.
Background
Radiotherapy (RT) is one of the major non-operative treat-
ment modalities used for treating carcinomas of various
organs, demonstrated by the fact that approximately half
of all cancer patients have been shown to receive RT
during their course of anti-cancer treatment [1, 2]. On-
going investigations have improved the survival of cancer
patients and minimized RT-related toxicities through the
design of new RT modalities, including 3-dimensional
conformal RT based on computed radiography imaging,
image-guided RT, stereotactic body RT, and intensity-
modulated (IM) RT [2]. Among these modalities, IMRT
was developed to deliver irregularly shaped radiation
doses as well as to save critical organs through the appli-
cation of inverse planning software and computer-
controlled intensity-modulation (2).
Tomotherapy (Accuray, Palo Alto, USA) is a form of
IMRT which is integrated with an image guidance system,
and helical tomotherapy delivers IMRT in a continuous
helix for improved dose conformity to malignant tissues
[3, 4]. Several oncologic diseases have been effectively and
safely treated with helical tomotherapy, including prostate
cancer, scalp angiosarcoma, hepatocellular carcinoma,
breast cancer, and lung cancer [4–9]. Helical tomotherapy
allows delivery of the radiation beam from any gantry
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angle as a result of continuous rotation around the pa-
tient, which results in the sparing of surrounding normal
tissues from unwanted excessive radiation [3]. Generally,
an increased fraction number has been considered to
reduce the risk of radiation-induced high-grade toxicities
[9]. However, unexpected pneumonitis may occur in
patients treated with helical tomotherapy, especially in
combination with chemotherapy, as a result of extensive
low-dose radiation of large lung volumes [9, 10].
To avoid this risk of radiation-induced pneumonitis, a
type of static tomotherapy using static gantry positions
has been introduced, and a dosimetric study demonstrated
optimaltarget volume coverage with adequate sparing of
normal tissue with static tomotherapy [11]. In the current
study, we compared the risk of radiation pneumonitis in
patients with lung cancer who received either helical
tomotherapy or static tomotherapy. In addition, we
developed rat models of radiation pneumonitis, which
were induced by helical tomography and static tomog-
raphy with or without concurrent chemoradiotherapy
(CCRT), respectively. Then, we evaluated the expression
of radiation pneumonitis-associated cytokines, including
transforming growth factor (TGF)-β, interleukin (IL)-1α,
IL-1β, and IL-6, to determine the effects of radiation on
surrounding normal lung tissues in each animal group.
Materials and methods
Patients
This study included 63 patients (43 males and 20 females;
median age, 66 years; age range, 33–87 years) diagnosed
with primary lung cancer who were treated with helical
tomotherapy or static tomotherapy. Baseline characteris-
tics of the participants are summarized in Table 1. The
patients were pathologically diagnosed by surgical lung
Table 1 Patients’ baseline demographics and characteristics
No. of patients (%)
Sex Male 43 (68.3)
Female 20 (31.7)
Age (years), median (range) 66 (33–87)
Smoking History Yes 36 (57.1)
No 27 (42.9)
Underlying COPD 3 (4.8)
Tumor locationa Right upper lobe 15 (23.8)
Right middle lobe 6 (9.5)
Right lower lobe 20 (31.7)
Left upper lobe 19 (30.2)
Left lower lobe 14 (22.2)
Histologic features Adenocarcinoma 24 (38.1)
Squamous cell carcinoma 16 (25.4)
Small cell lung cancer 12 (19.0)
Non-small cell lung cancer, NOS 9 (14.3)
Bronchoalveolar carcinoma 1 (1.6)
Large cell carcinoma 1 (1.6)
Aim of radiotherapy Definitive 26 (41.3)
Postoperative 1 (1.6)
Salvage 19 (30.1)
Palliative 17 (27.0)
Concurrent chemoradiotherapy Yes 21 (33.3)
No 42 (66.7)
PTV (cc), median (range) 144 (16–799)
Total lung V10 (%), median (range) 39 (5–93)
Total lung V20 (%), median (range) 16 (4–49)
Mode of tomotherapy Static 12 (19.0)
Helical 51 (81.0)
COPD chronic obstructive lung disease, PTV planning target volume, a; 11 patients have multi-lobar lesions
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biopsy and staged according to the consensus recommen-
dations of the International Association for the Study of
Lung Cancer International Staging Committee [12].
All of the patients underwent helical tomotherapy
(N = 51; 81.0 %) or static tomotherapy (N = 12; 19.0 %)
for RT with definitive, salvage, or palliative treatment pur-
poses. Tomotherapy was planned following the perform-
ance of chest computed tomography (CT), in which each
patient was scanned from the mandible to the lower edge
of the liver with 5-mm-thick slices. The gross tumor
volume (GTV) included the primary tumor and involved
regional lymphnodes, with a clinical target volume (CTV)
of GTV plus a 0.6–0.8 cm margin and a planning target
volume (PTV) of CTV plus a 0.5–1.0 cm margin. The
patients usually received tomotherapy in five fractions per
week at a radiation dose of 60–66 Gy in 2.0–2.2 Gy daily
fractions.
Tomotherapy planning was performed using the
TomoTherapy Hi-Art system version 4.0 (Accuray, Palo
Alto, CA, USA). The planning system employed an
inverse treatment planning process based on iterative least
squares minimization of an objective function. The simul-
taneous integrated boost method was used in the planning
for most patients. The importance factor placed con-
straints on the target and critical structures in relation to
each other and determined the degree of weighting for
achieving each prescription dose. For each target struc-
ture, a penalty factor was applied to the minimum and
maximum dose values, and for organs at risk, it was used
for the maximum dose. Each treatment plan was evalu-
ated with a dose-volume histogram. In general, plans were
considered acceptable if the PTV was covered by 95 % of
the isodose curves, inhomogeneity of the PTV ranged
from 95 % to 107 %, and doses to normal organs were lim-
ited in their tolerances. Dose tolerances for normal
structures were as follows: total lung V20 < 40 %, mean
lung dose (MLD) < 20 Gy, maximum dose to spinal cord
< 45 Gy, heart V60 < 33 %, and esophagus V45 < 33 %.
Among the total of 63 patients, 21 (33.3 %) patients
were treated with CCRT as either chemotherapy com-
bined with static-mode tomotherapy (static-CCRT; N = 7)
or helical-mode tomotherapy (helical-CCRT; N = 14).
Chemotherapy was performed with a treatment regimen
comprising cisplatin at a dose of 20–25 mg/m2/day on
days 1–3 and docetaxel at 65–70 mg/m2/day on day 1,
which was initiated simultaneously with tomotherapy.
During the course of RT, 1–2 cycles of chemotherapy were
concurrently administered, and after the complete of RT,
additional 2–3 cycles of chemotherapy followed within
4 weeks.
The diagnosis of radiation pneumonitis was based on
clinical symptoms, including dry cough, low-grade fever,
shortness of breath, and chest pain, as well as the radio-
logic findings on chest X-ray and CT scan read by at
least two radiologists. Most cases of acute radiation
pneumonitis occur between 6 and 12 weeks after the
conclusion of RT, whereas late radiation pneumonitis
generally presents after 6 months [13]. The risk of radi-
ation pneumonitis was evaluated by the grading systems
of both the Radiation Therapy Oncology Group (RTOG)
and the National Cancer Institute Common Termin-
ology Criteria for Adverse Events (CTCAE), version 3.0
[14]. Our experimental protocols were approved by the
Institutional Review Board of Severance Hospital at Yon-
sei University College of Medicine in Seoul, Korea.
Animal model and treatment protocol
Five-week-old Sprague–Dawley rats (N = 15, body weights
of 300–400 g) were divided into five groups; Group 1:
controls (N = 3), Group 2: rats treated with static
tomotherapy alone (N = 3), Group 3: helical tomotherapy
alone (N = 3), Group 4: static-CCRT (N = 3), and Group 5:
helical-CCRT (N = 3). Chemotherapy was performed by
intraperitoneal injection of gemcitabine (2′,2’-difluoro-2’-
deoxycytidine) (Eli Lilly and Company, Indianapolis, IN,
USA) at a dose of 5 mg/kg body weight as described previ-
ously [15]. RT was planned by CT simulation and a dose
of 12 Gy was delivered to the right lobe of the lung under
anesthesia with phenobarbital at a dose of 30 mg/kg
(Sigma-Aldrich Co. LLC, St. Louis, MO, USA). The left
lung was protected by a constraint set to minimize radi-
ation exposure in both helical and static tomotherapy.
Target regions were irradiated with a margin of at least
2 mm in width from the center in order to prevent radi-
ation esophagitis or myelitis. Other regions were protected
from irradiation with a multileaf collimator. The animal
studies were performed according to experimental proto-
cols that were approved by the Committee for the Care
and Use of Laboratory Animals of Severance Hospital.
The experiments were repeated twice. Similar patterns
were found between the first experiments and repeated
experiments.
Enzyme-linked immunosorbent assay
Peripheral blood levels of IL-1α (Abcam, Cambridge, UK)
and IL-1β (Abcam) were detected using enzyme-linked
immunosorbent assay (ELISA) kits according to the man-
ufacturers’ instructions. Peripheral blood samples were
obtained from tail veins of experimental rats for 1, 2, and
3 weeks after tomotherapy and CCRT. For ELISA, 2 mL
of peripheral blood was collected from each experimental
rat followed by isolation of serum. Samples with inad-
equate serum quantity or quality due to hemolysis were
excluded from biochemical measurements. Additionally,
serum samples were measured in triplicate and those
showing more than three-time variation from the mean
value were excluded from the study.
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Histological and immunohistochemical analysis
Tissues from the right and left lungs of experimental ani-
mals were obtained at 3 weeks after tomotherapy or
CCRT, fixed in 10 % buffered formalin, and embedded in
paraffin. Serial tissue sections of 4-μm thickness were pre-
pared for histological analysis with hematoxylin and eosin
(H&E) stain. Additionally, immunohistochemical stains
were performed with prepared tissue sections. Briefly, the
sections were deparaffinized with xylene and then rehy-
drated in graded ethanol. Antigen retrieval was achieved
by pressure-cooking using Antigen Retrieval Solution
(Dako, Carpinteria, CA, USA). Then, endogenous perox-
idase activity was blocked with Endogenous Enzyme Block
(Dako). The sections were incubated with primary anti-
bodies, including anti-IL-1α antibody (Abcam) and rabbit
anti-IL-1β polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at a dilution of 1:100, rabbit anti-
IL-6 polyclonal antibody (Abcam) at 1:50, and mouse
anti-TGF-β monoclonal antibody (Abcam) at 1:25 for 1 h
at room temperature. Real™EnVision™ HRP Rabbit/Mouse
detection system (Dako) was used as a secondary anti-
body, and the sections were then counterstained with
hematoxylin.
Rabbit anti-IgG antibody (R&D Systems GmbH,
Wiesbaden, Germany) or mouse anti-IgG antibody (Dako-
Cytomation GmbH, Hamburg, Germany) were used as
isotype-matched control antibodies at concentrations iden-
tical to those of the primary antibodies. The staining inten-
sity of the tumor cells was scored as 0 (negative), 1 (light
brown), 2 (brown), and 3 (dark brown). The final score was
calculated as (0 × % negative cells) + (1 × % light brown-
stained cells) + (2 × % brown-stained cells) + (3 × % dark
brown-stained cells) according to a weighted histoscore
method [16].
Statistical analysis
Expression of IL-1α, IL-1β, IL-6, and TGF-β in each group
was compared using the Mann–Whitney test. Statistical
analyses were carried out using SPSS software (version
14.0; SPSS Inc., Chicago, IL, USA) and the differences
were considered significant at a value of p less than 0.05.
Results
Frequency of pneumonitis in lung cancer patients treated
with tomotherapy
The frequency of radiation pneumonitis was comparatively
investigated in lung cancer patients who received tomother-
apy using either the helical or the static mode. A total of 63
patients were evaluated for acute radiation pneumonitis,
and 54 patients were then investigated for late radiation
pneumonitis as 9 patients expired over the course of
follow-up. The frequency of CCRT in the group of patients
treated with helical-mode tomotherapy was higher than in
those treated with the static mode (p = 0.04). However, both
acute and late pneumonitis of ≥ grade 2 according to the
RTOG and CTCAE scoring systems occurred more fre-
quently in the group of patients treated with helical-mode
tomotherapy than in those treated with the static mode
over the course of RT (Table 2). Additionally, statistical
analyses revealed that helical-mode tomotherapy resulted
in a significantly higher rate of late radiation pneumonitis
than static-mode tomotherapy when evaluated by the
RTOG and CTCAE scoring system (p = 0.001, and 0.01).
Table 2 A comparison of patient characteristics and radiation pneumonitis in lung cancer patients treated with tomotherapy
according to the delivery mode of radiation beams
Mode of tomotherapy P-value
Static Helical
Smoking History Yes 12/12 (83.3 %) 26/51 (51.0 %) 0.04
No 2/12 (16.7 %) 25/51 (49.0 %)
PTV (cc) Median (range) 158.50 (57–799) 144.00 (16–789) NS
Total lung V10 (%) median (range) 32.00 (11–70) 44.00 (5–98) NS
Total lung V20 (%) median (range) 16.00 (5–51) 16.00 (4–53) NS
CCRTx Yes 7/12 (58.3 %) 14/51 (27.5 %) 0.04
No 5/12 (41.7 %) 37/51 (72.5 %)
Radiation pneumonitis scoring system
RTOG Acute 3/ 12 (25.0 %) 15/51 (29.4 %) NS
Late 1/ 12 (8.3 %) 27/42 (64.3 %) 0.001
CTCAE Acute 3/ 12 (25.0 %) 20/51 (39.2 %) NS
Late 1/ 12 (8.3 %) 20/42 (47.6 %) 0.01
CCRTx concurrent chemoradiotherapy, RTOG Radiation Therapy Oncology Group, CTCAE the National Cancer Institute Common Terminology Criteria for Adverse
Events, version 3.0, NS not significant
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Of the radiotherapeutic parameters, late grade 2 or
worse radiation pneumonitis by CTCAE score was ob-
served in 28.9 % (11 of 38 patients) with a total lung V10
Gy of < 50 % and in 62.5 % (10 of 16 patients) with a total
lung V20 Gy of ≥ 60 % (p = 0.02). Acute grade 2 or worse
radiation pneumonitis by CTCAE scoring system was
observed in 10 (26.3 %) of 38 patients with a total lung
V20 Gy of < 20 % and in 13 (52.0 %) of 25 patients with a
total lung V20 Gy of ≥ 60 % (p = 0.04).
Plasma levels of IL-1α and IL-1β according to the
experimental rat groups
Plasma levels of IL-1α and IL-1β in each experimental rat
group were comparatively evaluated at 1 week, 2 weeks,
and 3 weeks after tomotherapy or CCRT. No significant
differences in the levels of expression of IL-1α and IL-1β
were found among the groups at 1 week or 2 weeks. How-
ever, there were significant differences among the groups
at 3 weeks after tomotherapy or CCRT; expression of IL-
1α was 1.8-fold (Group 2; p = 0.037), 1.6-fold (Group
3; p = 0.037), 3.1-fold (Group 4; p = 0.037), and 3.2-fold
(Group 5; p =0.037) higher compared to the control group
(Group 1) (Fig. 1a), and expression of IL-1β was also 13.5-
fold (Group 2; p =0.037), 16.6-fold (Group 3; p = 0.037),
20.3-fold (Group 4; p =0.037), and 27.1-fold (Group 5;
p = 0.037) higher (Fig. 1b).
The plasma levels of IL-1α at 3 weeks after the treat-
ments were significantly higher in the static-CCRT group
(Group 4) compared to the groups that received either
static tomography alone (Group 2; p = 0.047) or helical
tomotherapy alone (Group 3; p =0.047), as well as in the
helical-CCRT group (Group 5) compared to the groups
that received either static tomography alone (p =0.047)
or helical tomotherapy alone (p =0.047). However, the
plasma IL-1α levels were not significantly different be-
tween the groups that received static tomotherapy alone
and helical tomotherapy alone or between the static-
CCRT group and the helical-CCRT group.
Additionally, the plasma levels of IL-1β at 3 weeks
after the treatments were significantly higher in the
static-CCRT group compared to the groups that received
either static tomotherapy alone (p = 0.047) or helical
tomography alone (p = 0.047), as well as in the helical-
CCRT group compared to the groups that received ei-
ther static tomotherapy alone (p = 0.047) or helical tom-
ography alone (p = 0.047). Moreover, IL-1β expression was
significantly increased in the helical tomotherapy alone
group compared to the group that received static tomother-
apy alone (p = 0.047), as well as in the helical-CCRT group
compared to the static-CCRTgroup (p =0.047).
Tissue expression of IL-1α in the animal model
Lung specimens were obtained from the experimental rats
in each group at 3 weeks after tomotherapy or CCRT, and
tissue expression of IL-1α, IL-1β, IL-6, and TGF-β was eval-
uated using immunohistochemical staining and weighted
histoscoring. Right lung samples from the treatment groups
demonstrated 2.4-fold (Group 2, p = 0.037), 2.8-fold (Group
3, p = 0.037), 4.4-fold (Group 4, p = 0.037), and 5.8-fold
(Group 5, p = 0.037) higher tissue expression of IL-1α
compared to the untreated right lung samples (Group 1)
(Fig. 2a, c, d). Additionally, left lung samples from the treat-
ment groups showed 1.5-fold (Group 2, p = 0.037), 2.7-fold
(Group 3, p = 0.037), 4.2-fold (Group 4, p = 0.037), and 5.4-
fold (Group 5, p = 0.037) higher tissue expression of IL-
1α compared to the untreated left lung specimens of
Group 1 (Fig. 2b).
Both right and left lung samples obtained from the
rats in groups treated with CCRT were found to have
higher IL-1α expression compared to the groups treated
with RT alone (right lung, p = 0.004; left lung, p = 0.004).
Additionally, rats treated with helical tomotherapy alone
demonstrated significantly higher levels of IL-1α com-
pared to those treated with static tomotherapy alone
(right lung, p = 0.047; left lung, p = 0.047). Helical-CCRT
in rats resulted in significantly higher IL-1α expression
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compared to static-CCRT in both the right and left
lungs (p = 0.047 and p = 0.047, respectively).
Tissue expression of IL-1β in the animal model
Significantly upregulated tissue expression of IL-1β
was found in both right and left lung samples ob-
tained from rats in Group 2 (2.9-fold, p = 0.037; 2.5-fold,
p = 0.037, respectively), Group 3 (2.7-fold, p = 0.037; 2.9-
fold, p = 0.037, respectively), Group 4 (3.7-fold, p = 0.037;
3.3-fold, p = 0.037, respectively), and Group 5 (3.8-fold,
p = 0.037; 3.7-fold, p = 0.037, respectively) when com-
pared to the untreated control group (Group 1)
(Fig. 3a–d). Both right and left lung samples obtained
from the rats in groups treated with CCRT were found
to have higher IL-1β expression compared to the
groups treated with RT alone (right lung, p = 0.004; left
lung, p = 0.004). Rats treated with helical tomotherapy
alone demonstrated significantly higher tissue expres-
sion of IL-1β compared to those treated with static
tomotherapy alone in the left lung (p = 0.047), but not in
the right lung (p > 0.05). Additionally, rats treated with
helical-CCRT showed significantly higher IL-1β levels
compared to those treated with static-CCRT (right lung,
p > 0.05; left lung, p = 0.047).
Tissue expression of IL-6 in the animal model
Significantly upregulated tissue expression of IL-6 was
found in both right and left lung samples obtained from
rats in Group 2 (5.2-fold, p = 0.037; 3-fold, p = 0.037, re-
spectively), Group 3 (7.5-fold, p = 0.037; 4-fold, p = 0.025,
respectively), Group 4 (10-fold, p= 0.034; 8.5-fold, p= 0.037,
respectively), and Group 5 (14.5-fold, p = 0.037; 11-fold,
p = 0.037, respectively) when compared to the untreated
control group (Fig. 4a–d). Both right and left lung sam-
ples obtained from the CCRT-treated rats were found
to have higher IL-6 levels compared to the groups
treated with RT alone (right lung, P = 0.004; left lung,
p = 0.004). Rats treated with helical tomotherapy alone
demonstrated significantly higher IL-6 expression
compared to those treated with static tomotherapy alone
(right lung, p = 0.047; left lung, p = 0.037). Additionally,
helical-CCRT treatment resulted in remarkably higher
tissue IL-6 expression compared to static-CCRT treatment
(right lung, p = 0.046; left lung, p = 0.047).
Tissue expression of TGF-β in the animal model
Right lung samples from the treatment groups demon-
strated 15.7-fold (Group 2, p = 0.037), 14.2-fold (Group 3,
p = 0.037), 20.3-fold (Group 4, p = 0.037), and 25.3-fold
(Group 5, p = 0.037) higher tissue expression of TGF-β
compared to the right lung tissues of untreated controls
(Fig. 5a, c, and d). Additionally, left lung samples from the
treatment groups showed 2.5-fold (Group 2, p = 0.037), 5.5-
fold (Group 3, p =0.037), 10.5-fold (Group 4, p = 0.037),
and 21.2-fold (Group 5, p = 0.037) higher tissue TGF-β ex-
pression compared to the controls (Fig. 5b).
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Both right and left lung samples obtained from the rats
in groups treated with CCRT were found to have remark-
ably higher TGF-β expression compared to the RT alone
groups (right lung, p = 0.006; left lung, p = 0.004). Helical
tomotherapy alone induced significantly higher TGF-β ex-
pression in lung specimens compared to static tomotherapy
alone (right lung, p > 0.05; left lung, p = 0.047). Additionally,
rats treated with helical-CCRT demonstrated significantly
higher TGF-β expression compared to those treated with
static-CCRT (right lung, p = 0.047; left lung, p =0.047).
Discussion
Radiation-induced pneumonitis occurs in various can-
cerous conditions, including small cell or non-small cell
carcinoma of the lung, esophageal cancer, breast cancer,
and malignant lymphoma, as a complication of thoracic
RT [17]. In patients with lung cancers, the risk of radi-
ation pneumonitis is significantly correlated with the
dose and volume factors of RT [18]. When the total lung
volume receiving 20 Gy is less than 22 %, radiation
pneumonitis rarely occurs, whereas an 8 % risk of grade
2 radiation pneumonitis can be encountered in cases
with 22–31 % of the lung volume receiving 20 Gy [18].
Additionally, a dose-volume histogram analysis study
demonstrated that the dosimetric factors of normal tis-
sue complication probability, mean dose, and total lung
volume receiving ≥30 Gy were significantly associated
with radiation-induced pneumonitis [19].
The lung volume receiving high doses has been reduced
by the advent of IMRT, however, the risk of acute or late
pulmonary toxicity should be considered as the volume
receiving low doses has been increased [17, 20, 21].
Helical-mode tomotherapy delivers low-dose exposure of
almost the entire lung volume at target area level. Several
authors reported helical tomotherapy is safe and not asso-
ciated with a specific pattern of lung injury [22]. Donato
et al. assessed the toxicities of hypofractionated radiation
course delivered with helical tomotherapy, and they
reported acute grade 3 treatment-related pneumonitis was
detected in 10 % of patients. These findings not increased
the risk of radiation pneumonitis when compared with
other observed studies.
Song et al. assessed clinical outcomes in non-small-
cell lung cancer patients treated with chemotherapy and
helical tomotherapy, and reported four patients died of
treatment-related death after helical-mode radiotherapy
[23]. They suggested that helical tomotherapy has high
rate of fatal pulmonary complications. Kim et al. re-
ported low dose V5 of ipsilateral and contralateral lung
volume were also significant predictive factors for radi-
ation pneumonitis after helical tomotherapy [24]. They
recommended normal lung of V5, V10 and V15 should
be kept as low as possible. To reduce the chance of low-
dose irradiation to large areas of normal tissue, a type of
static tomotherapy, which uses static gantry positions,
has been performed in combination with multileaf
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collimator modulation and couch translation [11, 25].
The planning time of IMRT can be reduced in static-
mode tomotherapy by using specified beam angles com-
pared with the helical-mode [11, 25]. Additionally, the
beam-on time is lesser in the static-mode than in the
helical mode and conventional 3-dimensional conformal
RT [11]. Therefore, optimal target volume coverage with
adequate sparing of normal tissue (e.g.,lung volume) can
be achieved by using static-mode tomotherapy [25].
In this study, we compared the risk of radiation
pneumonitis between helical tomotherapy and static
tomotherapy in lung cancer patients. Although, the fre-
quency of CCRTx in the group of patients treated with
helical-mode tomotherapy was higher than in those
treated with the static mode (p = 0.04), they found that
helical-mode tomotherapy resulted in a significantly
higher rate of late radiation pneumonitis than static-mode
tomotherapy.
Additionally, we developed rat models of radiation
pneumonitis, which were induced by helical tomography
and static tomography. Our evaluation of tissue samples
from treated lung found that the expression of radiation-
induced inflammatory cytokines, including TGF-β, IL-1α,
IL-1β, and IL-6, was similarly increased in groups treated
with helical-mode and static-mode tomotherapy. How-
ever, when comparing samples from the opposite side of
the lung, we found that radiation-induced inflammatory
cytokines were significantly increased in rat groups treated
with helical-mode tomotherapy compared to those treated
with static-mode tomotherapy.
The risk of radiation-induced pulmonary toxicity is
remarkably increased by the concomitant systemic ther-
apy of CCRT [17]. However, dose-volume recommenda-
tions which are specific for CCRT have not been fully
established, with the exception of the recommendations
of total lung volume receiving 20 Gy and 30 Gy [17–19].
In our study, we found that animal models also exhibited
significantly remarkable pulmonary toxicity on the
treated side of the lungs in the groups that received
CCRT compared to those treated with helical-mode and
static-mode tomotherapy alone. Moreover, when compar-
ing the opposite side of the lung, we found that radiation-
induced inflammatory cytokines were increased in the rat
group treated with helical-CCRT compared to the static-
CCRT group.
Conclusion
In the present study, we found that rat models treated
with helical-mode or static-mode tomotherapy with or
without CCRT could present similar patterns of pulmon-
ary toxicity to those shown in lung cancer patients. Never-
theless, further studies are needed to establish an
appropriate animal model of radiation-induced pulmonary
toxicity to exactly reflect the radiation-induced human
tissue response. Additionally, we suggest that our study
can be used as a basic reference for developing an animal
model of radiation-induced pulmonary toxicity.
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